Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1

Journal of Virology

Volumn 85, Issue 19, 2011, Pages 10079-10089

  Koh, Yasuhiro ^a   Aoki, Manabu ^a,b   Danish, Matthew L ^a   Aoki Ogata, Hiromi ^a   Amano, Masayuki ^a   Das, Debananda ^c   Shafer, Robert W ^d   Ghosh, Arun K ^e   Mitsuya, Hiroaki ^a,c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO HEALTH SCIENCE UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; DIMERIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CELL LINE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIV PROTEASE; HIV-1; HUMANS; MUTANT PROTEINS; PROTEIN MULTIMERIZATION; SULFONAMIDES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80053992581     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05121-11     Document Type: Article

References (42)

1. Amano, M., et al. 2007. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) GRL-98065 potent against multi-PIresistant HIV in vitro. Antimicrob. Agents Chemother. 51:2143-2155.
2. Antiretroviral Therapy Cohort Collaboration. 2008. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372:293-299.
3. Aoki, M., et al. 2009. Non-cleavage site Gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors. J. Virol. 83:3059-3068.
4. Babe, L. M., J. Rose, and C. S. Craik. 1992. Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases. Protein Sci. 1:1244-1253.
5. Bastiaens, P. I., and T. M. Jovin. 1996. Microspectroscopic imaging tracks the intracellular processing of a signal transduction protein: fluorescentlabeled protein kinase C beta I. Proc. Natl. Acad. Sci. U. S. A. 93:8407-8412.
6. Bastiaens, P. I., I. V. Majoul, P. J. Verveer, H. D. Soling, and T. M. Jovin. 1996. Imaging the intracellular trafficking and state of the AB5 quaternary structure of cholera toxin. EMBO J. 15:4246-4253.
7. Bhaskaran, K., et al. 2008. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300:51-59.
8. De Meyer, S., et al. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:2314-2321.
9. de Meyer, S., et al. 2008. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res. Hum. Retroviruses 24:379-388.
10. Dierynck, I., et al. 2007. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J. Virol. 81:13845-13851.
11. Fang, G., B. Weiser, A. Visosky, T. Moran, and H. Burger. 1999. PCR-mediated recombination: a general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA. Nat. Med. 5:239-242.
12. Ferrer, E., et al. 2003. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. J. Infect. Dis. 187:687-690.
13. Gatanaga, H., et al. 2002. Amino acid substitutions in Gag protein at noncleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277:5952-5961.
14. Ghosh, A. K., et al. 1998. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg. Med. Chem. Lett. 8:687-690.
15. Ghosh, A. K., et al. 1998. Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors. Bioorg. Med. Chem. Lett. 8:979-982.
16. Ghosh, A. K., S. Leshchenko, and M. Noetzel. 2004. Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114). J. Org Chem. 69:7822-7829.
17. Ghosh, A. K., E. Pretzer, H. Cho, K. A. Hussain, and N. Duzgunes. 2002. Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease. Antiviral Res. 54:29-36.
18. Gupta, R., A. Hill, A. W. Sawyer, and D. Pillay. 2008. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin. Infect. Dis. 47:712-722.
19. Hoess, R. H., and K. Abremski. 1984. Interaction of the bacteriophage P1 recombinase Cre with the recombining site loxP. Proc. Natl. Acad. Sci. U. S. A. 81:1026-1029.
20. Hong, L., J. A. Hartsuck, S. Foundling, J. Ermolieff, and J. Tang. 1998. Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant. Protein Sci. 7:300-305.
21. Hong, L., X. C. Zhang, J. A. Hartsuck, and J. Tang. 2000. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci. 9:1898-1904.
22. Ishima, R., et al. 2001. Folded monomer of HIV-1 protease. J. Biol. Chem. 276:49110-49116.
23. Ishima, R., D. A. Torchia, S. M. Lynch, A. M. Gronenborn, and J. M. Louis. 2003. Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor. J. Biol. Chem. 278:43311-43319.
24. Koh, Y., et al. 2010. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J. Virol. 84: 11961-11969.
25. Koh, Y., et al. 2009. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 53:997-1006.
26. Koh, Y., et al. 2007. Potent inhibition of HIV-1 replication by novel nonpeptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem. 282:28709-28720.
27. Koh, Y., et al. 2003. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47:3123-3129.
28. Kohl, N. E., et al. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U. S. A. 85:4686-4690.
29. Little, S. J., et al. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
30. Louis, J. M., R. Ishima, D. A. Torchia, and I. T. Weber. 2007. HIV-1 protease: structure, dynamics, and inhibition. Adv. Pharmacol. 55:261-298.
31. Louis, J. M., I. T. Weber, J. Tozser, G. M. Clore, and A. M. Gronenborn. 2000. HIV-1 protease: maturation, enzyme specificity, and drug resistance. Adv. Pharmacol. 49:111-146.
32. Mitsuya, H., and J. Erickson. 1999. Discovery and development of antiretroviral therapeutics for HIV infection, p. 751-780. In T. C. Merigan, J. G. Bartlet, and D. Bolognesi (ed.), Textbook of AIDS Medicine. Williams & Wilkins, Baltimore, MD.
33. Mitsuya, Y., T. F. Liu, S. Y. Rhee, W. J. Fessel, and R. W. Shafer. 2007. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J. Infect. Dis. 196:1177-1179.
34. Murphy, E. L., et al. 2001. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135:17-26.
35. Sekar, R. B., and A. Periasamy. 2003. Fluorescence resonance energy transfer (FRET) microscopy imaging of live cell protein localizations. J. Cell Biol. 160:629-633.
36. Szczesna-Skorupa, E., B. Mallah, and B. Kemper. 2003. Fluorescence resonance energy transfer analysis of cytochromes P450 2C2 and 2E1 molecular interactions in living cells. J. Biol. Chem. 278:31269-31276.
37. Tojo, Y., et al. 2010. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro. Antimicrob. Agents Chemother. 54:3460-3470.
38. Van Marck, H., et al. 2009. The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence. J. Virol. 83:9512-9520.
39. Walensky, R. P., et al. 2006. The survival benefits of AIDS treatment in the United States. J. Infect. Dis. 194:11-19.
40. Wlodawer, A., et al. 1989. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245:616-621.
41. Yoshimura, K., et al. 2002. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 76:1349-1358.
42. Yoshimura, K., et al. 1999. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. U. S. A. 96:8675-8680.